PADRES (NCT03438708): Phase 2 Clinical Trial of Neoadjuvant Axitinib for Complex Partial Nephrectomy.

Kevin HakimiSteven C CampbellMimi V NguyenNityam RathiLuke WangMargaret F MeagherBrian I RiniMoshe OrnsteinRana R McKayIthaar H Derweesh

Published in: BJU international (2023)

Neoadjuvant axitnib resulted in reductions in tumor size and complexity, enabling safe and feasible PN and functional preservation in patients with complex renal masses and imperative indication.

Keyphrases

rectal cancer
clinical trial
locally advanced
lymph node
squamous cell carcinoma
study protocol
magnetic resonance imaging
phase ii
radiation therapy
randomized controlled trial
double blind
ultrasound guided
fine needle aspiration